Skip to main content


Latest articles

16-12-2020 | Diabetes | News | Article

‘Counterintuitive’ HAPO FUS findings challenge large baby metabolic concerns

The latest analysis of HAPO and HAPO FUS data indicates that, contrary to prior assumptions, a high birthweight and newborn adiposity are associated with good metabolic health in childhood.

16-12-2020 | Diabetes | News | Article

Similar visual outcomes may be achieved with aflibercept vs vitrectomy

Intravitreous aflibercept and vitrectomy with panretinal laser photocoagulation appear to have similar efficacy over 24 weeks when used for the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, researchers report.

15-12-2020 | Diabetes | News | Article

Diabetes in dogs could serve as early warning to owners

A dog with diabetes may be a novel early warning sign for diabetes risk in its owner, according to a study in the Christmas edition of The BMJ.

14-12-2020 | Diabetes | News | Article

Support for bariatric surgery in people with insulin-dependent type 2 diabetes

Treatment with bariatric surgery is associated with clinical and cost-saving benefits among obese people with type 2 diabetes requiring insulin, researchers report.

11-12-2020 | Diabetes | News | Article

Racial minorities have reduced likelihood of receiving diabetes technologies

US researchers have identified racial disparities in the receipt of diabetes technologies among young adults with type 1 diabetes.

10-12-2020 | Diabetes | News | Article

DKA linked to concurrent kidney, brain injury in children

Acute kidney injury is common in children with diabetic ketoacidosis and is associated with circulatory volume depletion, greater acidosis, and signs of cerebral injury, US study data show.

09-12-2020 | Diabetes | News | Article

Dapagliflozin offers cardiorenal benefit regardless of pre-existing CVD

Dapagliflozin reduces the risk for adverse renal outcomes, and also adverse cardiovascular outcomes and mortality, shows a prespecified subgroup analysis of DAPA-CKD.

09-12-2020 | Diabetes | News | Article

Liraglutide gets FDA go-ahead for teens with obesity

Click through to read more on this announcement

08-12-2020 | Diabetes | News | Article

Metformin might protect women with type 2 diabetes against COVID-19 mortality

An observational study suggests that prior metformin use may offer a protective effect against COVID-19 mortality in people with type 2 diabetes, but only for women.

07-12-2020 | Diabetes | News | Article

Emotional regulation ‘meaningfully linked’ to diabetes distress

Negative emotional experience and skill at regulating emotions are associated with diabetes distress in adults with type 1 or type 2 diabetes, researchers report.

04-12-2020 | Diabetes | News | Article

EMPA-REG OUTCOME: Empagliflozin reduces total CV burden in type 2 diabetes

Empagliflozin reduces the total burden of cardiovascular complications and all-cause hospitalization in people with type 2 diabetes and atherosclerosis, show data from the EMPA-REG OUTCOME trial.

03-12-2020 | Diabetes | News | Article

‘Remarkably high’ lifetime risk for developing diabetes in metropolitan cities in India

People living in metropolitan cities in India have a high likelihood of developing diabetes, with a particularly elevated risk in overweight and obese individuals, research shows.

03-12-2020 | Diabetes | News | Article

Finerenone may have both primary and secondary CVD prevention benefits

A prespecified analysis of the FIDELIO-DKD trial shows that finerenone reduces the risk for cardiovascular disease events in people with type 2 diabetes and chronic kidney disease, irrespective of whether they have pre-existing heart disease.

02-12-2020 | Diabetes | News | Article

Real-world data support early insulin pump initiation in children

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.

01-12-2020 | Diabetes | News | Article

Real-world data support improved glycemic control with faster aspart

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

27-11-2020 | Diabetes | News | Article

Healthy lifestyle mitigates elevated heart disease risk in people with type 2 diabetes

People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.

26-11-2020 | Diabetes | News | Article

Type 2 diabetes linked to increased CVD risk even without CV risk factors

The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.

25-11-2020 | Diabetes | News | Article

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

25-11-2020 | Diabetes | News | Article

More than half of people with type 2 diabetes at very high CV risk

A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”

24-11-2020 | Diabetes | News | Article

Age has no impact on CV outcomes with linagliptin vs glimepiride

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.